AngioDesign is at the forefront of developing next-generation drugs through targeted molecular recognition, specifically focusing on Angiotensin-Converting Enzyme (ACE) as a therapeutic target. The company employs advanced 3-D structure-guided design techniques to create a new class of domain-selective ACE inhibitors. These inhibitors are designed to work in conjunction with other inhibitors, such as neprilysin (NEP), to effectively manage cardiovascular diseases and other non-communicable diseases. By utilizing crystal structures of ACE, AngioDesign has gained critical insights into the enzyme's active site, enabling the rational design of drugs that can selectively inhibit specific domains of ACE, thereby minimizing side effects commonly associated with traditional ACE inhibitors.

The innovative approach taken by AngioDesign includes the engineering of minimally glycosylated protein forms of ACE, which facilitates successful crystallization and high-resolution structure determination. This foundational work has led to the development of dual C-domain/NEP inhibitors that not only lower blood pressure but also normalize blood vessel contraction without adversely affecting vascular permeability. The company’s proprietary knowledge and patented technology position it uniquely in the market, allowing for the creation of safer and more effective treatments for hypertension and heart failure. With ongoing research and collaborations, AngioDesign aims to expand its pipeline of products and further explore the therapeutic potential of its domain-selective inhibitors across various disease areas.

United States

AngioDesign is developing the first truly-novel, next-generation combination inhibitors (C-domain ACE, C-domain ACE/NEP, N-domain ACE) with the potential to treat a number of the most important conditions impacting human health today, including heart failure, hypertension and fibrosis. Cardiovascular disease is the single most common cause of death in the world.

AngioDesign’s drug discovery platform is focused on the rational design and development of improved, next-generation drugs for proven disease targets and its initial focus is on the development of inhibitors of angiotensin-converting enzyme. AngioDesign uses a lean management approach in its quest to optimize this effort.

AngioDesign

Company Details